Safety of Bruton kinase inhibitors in chronic lymphocytic leukemia: Real world clinical practice
{{output}}
Introduction: Bruton's tyrosine kinase inhibitors (BTKi) have replaced immunochemotherapy in patients with chronic lymphocytic leukemia (CLL). The safety profile, particularly in monotherapy indications under real-world clinical... ...
